GlassScriptPhysician profile
Patricia A Sanchez Fermin
NPI 1225068208
$12,918.84
in general payments reported to CMS, 2019-2025
41 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,543 · 2020: $793 · 2021: $1,611 · 2022: $1,870 · 2023: $1,685 · 2024: $3,266 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,055 · Consulting Fee: $1,000 · Education: $46.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,054.56 |
| Consulting Fee | $1,000.00 |
| Education | $46.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,423.29 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Ardelyx, INC. | $1,282.53 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $1,007.15 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $994.70 | 2019-2025 | Xifaxan, Plenvu |
| Intercept Pharmaceuticals, INC. | $717.24 | 2019-2025 | Ocaliva |
| Janssen Biotech, INC. | $683.61 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $655.60 | 2022-2025 | |
| Qol Medical, LLC | $405.79 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $339.18 | 2021-2023 | Zeposia |
| Pfizer INC. | $327.78 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $303.54 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $249.57 | 2024-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $244.91 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $220.49 | 2019-2025 | Rebyota |
| Redhill Biopharma INC. | $205.18 | 2020-2024 | Talicia |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Sanchez Fermin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.